Phase 2 Randomised controlled trial of bone-marrow derived mesenchymal stromal cells (MSC) for new onset chronic lung allograft dysfunction (CLAD)

This study tests whether infusions of special stem cells called mesenchymal stromal cells (MSC) can slow or stop a serious lung condition called chronic lung allograft dysfunction (CLAD) in people who have had a lung transplant. CLAD causes the transplanted lungs to gradually stop working, and there is currently no reliable treatment. Participants receive four infusions over two weeks and are followed for a year to monitor lung function. You may be eligible if: - You are 18 years of age or older and have had a bilateral (two-lung) transplant at least 6 months ago - You have recently developed CLAD (a persistent drop in lung function of 20% or more in the past 12 months) - Other causes of lung function decline (like infection or rejection) have been ruled out - Your immunosuppression medications have been stable for 4 weeks - You are available for all required study visits and procedures, including bronchoscopies You may NOT be eligible if: - You have an untreated rejection or active infection - You have received certain treatments (macrolide antibiotics, IV steroids, photopheresis, or radiation) in the past 4 weeks - You are pregnant or breastfeeding - You are allergic to beef products - You are enrolled in another interventional clinical trial Talk to your doctor about whether this trial might be right for you.